Actively Recruiting

Phase 1
Age: 18Years - 45Years
All Genders
Healthy Volunteers
ID07366866

A Single-center, Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of GenSci136 for Injection in Healthy Adult Participants in China

Led by Changchun GeneScience Pharmaceutical Co., Ltd. · Updated on 2026-03-25

48

Participants Needed

1

Research Sites

4 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GenSci136 in healthy adult volunteers. This randomized, double-blind, placebo-controlled Phase 1 trial aims to study a single subcutaneous injection of GenSci136. The study focuses on how the drug behaves in the body and its effects, while monitoring for any adverse reactions over time. Participants will receive single ascending doses of GenSci136 or a placebo administered under the skin. The study is designed with dose escalation to evaluate different amounts of the drug. Both the experimental drug and placebo are given through subcutaneous injections in a controlled setting. During the study, participants will be closely observed from Day 1 through Day 113. Researchers will monitor for treatment-emergent adverse events and serious adverse events to assess safety. Blood samples will be collected to measure drug concentration, its maximum level, time to reach maximum level, elimination half-life, and other pharmacokinetic parameters. In addition, changes in specific biomarkers related to immune response will be measured. The trial involves regular visits and assessments over approximately 16 weeks to ensure thorough monitoring and data collection.

CONDITIONS

Brief Title

A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci136 in Healthy Adults.

Who Can Participate

Age: 18Years - 45Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female, aged 18 to 45 years at the time of signing informed consent.
  • Male body weight at least 50 kg or female body weight at least 45 kg; BMI between 18 and 28 kg/m2 at screening.
  • Males of reproductive age and females of childbearing potential must agree to use highly effective contraception during the study and not plan conception or donation; females must have a negative pregnancy test and not be breastfeeding.
  • Able to understand trial procedures, voluntarily participate, sign informed consent, follow trial requirements, and complete the study.
Not Eligible

You will not qualify if you...

  • Known allergy or serious hypersensitivity to GenSci136 or its ingredients, or history of serious allergic reactions to drugs, compounds, food, or other substances.
  • Presence of tattoo, sunburn, scar, or other factors interfering with injection site assessment.
  • History or presence of significant metabolic, skin, liver, kidney, blood, heart, digestive, neurological, respiratory, or other major diseases that could affect study evaluation.
  • Major surgery within 3 months before screening, planned elective surgery during the study, or past surgery affecting drug absorption or metabolism.
  • Positive alcohol breath test, recent drug abuse or use of drugs such as marijuana within 3 months, or harder drugs within 1 year before screening, or positive drug screening.
  • Judged ineligible by the investigator for other reasons.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Treatment

Duration - Up to 113 days

Participants receive a single subcutaneous injection of either GenSci136 or placebo to evaluate safety and pharmacokinetics.

Multiple visits for safety and pharmacokinetic assessments from Day 1 to Day 113

Trial Site Locations

Total: 1 location

1

Huashan Hospital

Shanghai, Shanghai Municipality, China, 200040

Actively Recruiting

Loading map...

Research Team

J

Jingsi Li

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

OTHER

Number of Arms

2

Similar Trials

Natural History and Genetics of VEXAS Syndrome and Related A...

VEXAS Syndome

Actively Recruiting

2 locations

An Exploratory Clinical Study to Evaluate Safety and Efficac...

Autoimmune Disease

Actively Recruiting

1 location

Natural History of Bronchiectasis Study to Understand Causes...

Bronchiectasis

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here